MetaCap

Coherus Oncology Inc. (CHRS)

NASDAQ: CHRSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.3698-0.0173 (-4.47%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CHRS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$57.15M
EPS (TTM)
-$1.12
52-week range
0.3628 – 2.62
Day range
0.3628 – 0.4084
Volume / Avg
2.52M / 1.80M
Beta
—

52-week range

$0.3628$2.62

CHRS stock today

Shares of Coherus Oncology (CHRS) finished lower on Nov 20 at $0.3698, a drop of 4.47% or $0.0173 per share, versus the S&P 500's 3.70% decline. At this level, CHRS sits near the bottom of its 52-week range of $0.3628 to $2.62: 85.9% below the high, set on Jan 27, 2026 and 1.9% above the low. CHRS is down 74.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 68.1%.

Coherus Oncology has posted a net loss over the last twelve months (EPS of -$1.12), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Coherus Oncology

Company profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Dennis M. Lanfear
Headquarters
Redwood City, CA
Employees
144
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, Coherus Oncology generated $42.2 million in revenue, up 59.8% from fiscal 2024. Net income was $168.0 million (+489.4% year over year), for a net margin of 398.4% versus a median of -87.9% in the prior 5 years. Gross margin was 67.2% (up from 66.9%) and operating margin -429.5%.

Coherus Oncology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$42.17M$26.39M$257.24M$211.04M$326.55M
Growth+59.81%-89.74%+21.89%-35.37%-31.37%
Net income$168.02M$28.51M$-237.89M$-291.75M$-287.10M
EPS (diluted)$1.43$0.25$-2.53$-3.76$-3.81

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$7.75+1995.73%

  • Strong buy 1
  • Buy 4
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.38 vs $-0.22
Surprise
-72.73%

CHRS news

All CHRS news

Coherus Oncology peers

Health Care sector
CHRS peer companies
CompanyPrice% ChgMarket capCompare
OKYOOKYO Pharma Limited1.07-7.76%$56.15Mvs CHRS
CGTXCognition Therapeutics Inc.0.5822-3.06%$55.37Mvs CHRS
AVXLAnavex Life Sciences Corp.0.5915-11.39%$54.83Mvs CHRS
CSBRChampions Oncology Inc.4.34-1.36%$60.41Mvs CHRS
NMRANeumora Therapeutics Inc.0.3339-3.78%$63.01Mvs CHRS
ATRAAtara Biotherapeutics Inc.6.33-0.16%$64.49Mvs CHRS
TNYATenaya Therapeutics Inc.0.2866-3.99%$65.32Mvs CHRS
IMAImageneBio Inc.3.920.00%$48.83Mvs CHRS

Indexes, lists and sector

Coherus Oncology stock FAQ

What is Coherus Oncology's stock price today?

CHRS last traded at $0.3698 as of Nov 20, 4:00 PM EST, down 4.47% on the day. Prices are delayed at least 15 minutes.

Who is Coherus Oncology's CEO?

Mr. Dennis M. Lanfear is the chief executive officer of Coherus Oncology Inc., which has about 144 employees.

What is the CHRS 52-week high?

The 52-week high for CHRS is $2.62 and the 52-week low is $0.3628. The stock is currently 85.9% below its high.

Compare CHRS